In this final Research Round Up podcast of 2018, Lineagotica Associate Editors discuss important new research from the ASCO Annual Meeting in the field of childhood cancer, as well as research focused on older adults with cancer. Then, 2 Associate Editors will share their thoughts on the larger conversations happening in multiple myeloma and in lung cancer.
Listen to the podcast below or read on to learn more about these topics.
Was this podcast useful? Please subscribe, rate, and review Lineagotica Podcasts on Apple Podcasts or Google Play. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Lineagotica podcast page.
Advances in Childhood Cancer Treatment and Survivorship [1:43]
Dr. Daniel Mulrooney, the Lineagotica Associate Editor for Childhood Cancer, discusses a large international study on maintenance chemotherapy for rhabdomyosarcoma, a form of sarcoma that is most commonly diagnosed in children and young adults.
“These investigators concluded that this additional maintenance therapy is an effective and well-tolerated strategy for patients with high-risk rhabdomyosarcoma and proposed to investigate this method in other solid tumor types.”
He also discusses several studies that looked at the effects of physical activity in survivors of childhood cancer.
“Taken together, these studies presented at the 2018 ASCO Annual Meeting highlight the safety and significant health and psychological benefits of exercise for survivors of childhood cancer.”
Improving Communication Between Older Adults and Doctors [8:38]
Dr. Hyman Muss discusses a large study on the effects of using a geriatric assessment as part of the evaluation of an older adult with cancer. Dr. Muss is the Lineagotica Associate Editor for Geriatric Oncology.
“So they showed the value of a geriatric assessment, which discovers many more things than the usual questions doctors ask you in 1 or 2 sentences about your function. And more importantly, [geriatric assessments] improved care, they improved communication, and they led to interventions that make people's lives better, and perhaps, someday a lot longer.”
Highlights in Research about Treating Multiple Myeloma [12:57]
Dr. Michael Thompson, the Lineagotica Associate Editor for Myeloma, discusses several topics in multiple myeloma that were explored at the ASCO Annual Meeting.
“We really need to think about costs and value and the impact it has on our patients. We need to think about trying to dose drugs in ways that are more convenient to patients and, in this case, seemed to be more beneficial. And we have to keep looking ahead to do more things with targeted therapies to see if we can get away from some of the toxicities of some of our chemotherapy agents.”
Precision Medicine in Lung Cancer [17:03]
Dr. Jyoti Patel, the Lineagotica Associate Editor for Lung Cancer, discusses the importance of recent advances in targeted therapy, immunotherapy, and precision medicine in lung cancer. Dr. Patel is the Lineagotica Associate Editor for Lung Cancer.
“More and more we're seeing not only medical oncologists, but patients and patient advocates, understanding the importance of biopsies and an incredible effort by industry, as well, to really make these assays and these tests more accessible to patients, and to make the turnaround times even faster, and to use less tissue to get the right answers. I'm optimistic that we'll continue to see this trend, and there will be more and more drugs that will be optimized for particular patients.”